brexpiprazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
psychotropics, phenylpiperazine derivatives	5014	913611-97-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: brexpiprazole rexulti OPC-34712 OPC 34712	an atypical antipsychotic the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors Molecular weight: 433.57 Formula: C25H27N3O2S CLOGP: 4.90 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 44.81 ALOGS: -5.28 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

brexpiprazole
rexulti
OPC-34712
OPC 34712

an atypical antipsychotic the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors

Molecular weight: 433.57
Formula: C25H27N3O2S
CLOGP: 4.90
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 44.81
ALOGS: -5.28
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	1.46 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.34 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	54.37 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ
BA (Bioavailability)	1 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company
July 27, 2018	EMA	OTSUKA PHARM CO LTD
July 10, 2015	FDA	OTSUKA PHARM CO LTD
Jan. 19, 2018	PMDA	Otsuka Pharmaceutical Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Akathisia	530.32	23.50	134	6518	9012	63473358
Schizoaffective disorder	437.86	23.50	96	6556	3466	63478904
Weight increased	357.22	23.50	260	6392	260532	63221838
Tardive dyskinesia	350.17	23.50	95	6557	8407	63473963
Drug level increased	258.19	23.50	95	6557	22641	63459729
Electrocardiogram QT prolonged	204.13	23.50	107	6545	59423	63422947
Product use in unapproved indication	163.28	23.50	141	6511	178939	63303431
Off label use	125.06	23.50	239	6413	674223	62808147
Restlessness	118.41	23.50	59	6593	29394	63452976
Tremor	118.08	23.50	103	6549	132136	63350234
Hallucination, auditory	110.99	23.50	44	6608	12780	63469590
Suicidal ideation	95.71	23.50	67	6585	62354	63420016
Mania	95.18	23.50	39	6613	12328	63470042
Drug interaction	91.38	23.50	116	6536	229015	63253355
Extrapyramidal disorder	82.59	23.50	36	6616	13248	63469122
Oculogyric crisis	79.12	23.50	21	6631	1700	63480670
Product administered to patient of inappropriate age	74.15	23.50	23	6629	3245	63479125
Inability to afford medication	72.67	23.50	21	6631	2326	63480044
Discoloured vomit	71.54	23.50	17	6635	877	63481493
Sinus rhythm	61.90	23.50	15	6637	841	63481529
Anxiety	52.64	23.50	87	6565	217454	63264916
Therapy cessation	49.71	23.50	34	6618	30423	63451947
Depression	48.08	23.50	79	6573	196413	63285957
Collagen-vascular disease	44.81	23.50	8	6644	96	63482274
Anger	44.33	23.50	23	6629	12433	63469937
Eye movement disorder	41.97	23.50	17	6635	5211	63477159
Food craving	39.38	23.50	12	6640	1594	63480776
Dystonia	39.34	23.50	22	6630	13797	63468573
Dyskinesia	39.15	23.50	30	6622	31972	63450398
Wrong technique in product usage process	37.30	23.50	39	6613	62301	63420069
Insomnia	36.68	23.50	74	6578	215178	63267192
Parakeratosis	36.49	23.50	8	6644	287	63482083
Psychiatric symptom	35.23	23.50	15	6637	5208	63477162
Product use issue	34.27	23.50	73	6579	220447	63261923
Sedation	34.07	23.50	30	6622	38779	63443591
Blood prolactin increased	33.75	23.50	13	6639	3490	63478880
Compulsive shopping	33.65	23.50	9	6643	750	63481620
Suicidal behaviour	33.53	23.50	12	6640	2627	63479743
Internal haemorrhage	32.10	23.50	14	6638	5151	63477219
Drug effective for unapproved indication	30.70	23.50	12	6640	3352	63479018
Seborrhoeic dermatitis	30.17	23.50	9	6643	1112	63481258
Feeling abnormal	30.15	23.50	55	6597	148337	63334033
Muscle twitching	29.84	23.50	21	6631	19647	63462723
Underdose	29.82	23.50	24	6628	27432	63454938
Hypomania	29.37	23.50	14	6638	6316	63476054
Dissociation	28.72	23.50	11	6641	2908	63479462
Hunger	28.37	23.50	13	6639	5366	63477004
Incorrect dose administered	28.07	23.50	33	6619	59935	63422435
Parkinsonism	28.04	23.50	16	6636	10423	63471947
Binge eating	27.58	23.50	7	6645	475	63481895
Agitation	26.52	23.50	32	6620	59725	63422645
Increased appetite	26.51	23.50	15	6637	9615	63472755
Delusion	25.95	23.50	16	6636	12001	63470369
Treatment noncompliance	25.32	23.50	25	6627	37300	63445070
Gambling disorder	25.02	23.50	8	6644	1244	63481126
Cutaneous T-cell lymphoma	24.26	23.50	8	6644	1372	63480998
Lactation disorder	23.98	23.50	6	6646	384	63481986

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Akathisia	331.48	37.60	85	2707	8024	34946115
Weight increased	120.91	37.60	81	2711	92952	34861187
Tardive dyskinesia	108.49	37.60	33	2759	5757	34948382
Product use in unapproved indication	82.75	37.60	71	2721	117428	34836711
Hallucination, auditory	71.18	37.60	29	2763	11888	34942251
Product administered to patient of inappropriate age	66.97	37.60	20	2772	3271	34950868
Suicidal ideation	66.72	37.60	41	2751	40347	34913792
Restlessness	63.95	37.60	34	2758	25448	34928691
Anxiety	59.78	37.60	55	2737	99373	34854766
Psychotic disorder	59.60	37.60	32	2760	24420	34929719
Off label use	52.92	37.60	108	2684	419416	34534723
Apathy	48.79	37.60	19	2773	6913	34947226
Loss of libido	45.45	37.60	14	2778	2538	34951601
Inability to afford medication	43.67	37.60	12	2780	1458	34952681
Hypomania	38.06	37.60	12	2780	2347	34951792

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Akathisia	281.24	24.59	82	5907	13177	79725222
Tardive dyskinesia	281.12	24.59	78	5911	10493	79727906
Product use in unapproved indication	198.76	24.59	158	5831	250201	79488198
Weight increased	170.36	24.59	151	5838	277235	79461164
Hallucination, auditory	168.41	24.59	62	5927	20631	79717768
Product administered to patient of inappropriate age	107.39	24.59	32	5957	5521	79732878
Tremor	97.03	24.59	89	5900	169994	79568405
Suicidal ideation	96.42	24.59	64	5925	76276	79662123
Restlessness	94.85	24.59	53	5936	46439	79691960
Oculogyric crisis	88.70	24.59	24	5965	2928	79735471
Anxiety	72.27	24.59	91	5898	248421	79489978
Off label use	70.11	24.59	186	5803	907029	78831370
Discoloured vomit	68.67	24.59	17	5972	1461	79736938
Dissociation	60.03	24.59	19	5970	4002	79734397
Inability to afford medication	58.07	24.59	17	5972	2756	79735643
Apathy	50.72	24.59	23	5966	12954	79725445
Collagen-vascular disease	48.36	24.59	8	5981	85	79738314
Psychotic disorder	45.78	24.59	32	5957	41370	79697029
Loss of libido	45.58	24.59	14	5975	2671	79735728
Depression	40.08	24.59	64	5925	216726	79521673
Dystonia	39.85	24.59	23	5966	21376	79717023
Neuroleptic malignant syndrome	39.40	24.59	25	5964	27534	79710865
Dyskinesia	39.08	24.59	30	5959	44743	79693656
Anger	38.93	24.59	21	5968	17141	79721258
Delusion	38.16	24.59	22	5967	20401	79717998
Hypomania	38.04	24.59	16	5973	7528	79730871
Insomnia	36.86	24.59	66	5923	245104	79493295
Parakeratosis	36.83	24.59	8	5981	386	79738013
Parkinsonism	36.80	24.59	20	5969	16564	79721835
Psychiatric symptom	35.74	24.59	15	5974	7020	79731379
Treatment noncompliance	34.99	24.59	30	5959	52238	79686161
Schizophrenia	32.55	24.59	18	5971	15422	79722977
Hallucination	32.47	24.59	36	5953	85709	79652690
Suicidal behaviour	31.15	24.59	11	5978	3236	79735163
Underdose	30.66	24.59	23	5966	33128	79705271
No adverse event	30.45	24.59	24	5965	37168	79701231
Persecutory delusion	30.17	24.59	12	5977	4897	79733502
Suicide attempt	30.00	24.59	34	5955	82898	79655501
Internal haemorrhage	29.37	24.59	14	5975	8819	79729580
Sedation	29.20	24.59	27	5962	51868	79686531
Hunger	29.01	24.59	12	5977	5416	79732983
Blood prolactin increased	28.89	24.59	11	5978	4000	79734399
Extrapyramidal disorder	28.55	24.59	19	5970	22660	79715739
Product use issue	28.39	24.59	54	5935	209768	79528631
Feeling abnormal	28.03	24.59	46	5943	159153	79579246
Gambling disorder	27.88	24.59	9	5980	2017	79736382
Seborrhoeic dermatitis	27.68	24.59	9	5980	2064	79736335
Mania	27.19	24.59	17	5972	18243	79720156
Altered state of consciousness	27.01	24.59	24	5965	43798	79694601
Completed suicide	27.00	24.59	58	5931	245709	79492690
Agitation	26.52	24.59	35	5954	99680	79638719
Compulsive shopping	26.23	24.59	7	5982	809	79737590
Wrong technique in product usage process	26.23	24.59	30	5959	73845	79664554
Egocentrism	25.49	24.59	3	5986	0	79738399
Bruxism	25.30	24.59	10	5979	4016	79734383

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AX16	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Other antipsychotics
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018491	Dopamine Agonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
FDA EPC	N0000175430	Atypical Antipsychotic

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Schizophrenia	indication	58214004	DOID:5419
Major depressive disorder	indication	370143000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.14	acidic
pKa2	8.07	Basic
pKa3	0.9	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	May 10, 2026	TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	May 10, 2026	TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	May 10, 2026	TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	May 10, 2026	TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	May 10, 2026	TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	May 10, 2026	TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	Ki	9.52	SCIENTIFIC LITERATURE	DRUG LABEL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	AGONIST	Ki	9.92	SCIENTIFIC LITERATURE	DRUG LABEL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	9.33	SCIENTIFIC LITERATURE	DRUG LABEL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	7.23	SCIENTIFIC LITERATURE
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	7.17	SCIENTIFIC LITERATURE
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	AGONIST	Ki	6.80	SCIENTIFIC LITERATURE
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	7.82	SCIENTIFIC LITERATURE
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	IC50	7.54	SCIENTIFIC LITERATURE
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	IC50	6.86	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN	ANTAGONIST	Ki	8.72	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.47	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.24	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN	ANTAGONIST	Ki	8.43	SCIENTIFIC LITERATURE
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.77	SCIENTIFIC LITERATURE
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	Ki	8.96	SCIENTIFIC LITERATURE
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	7.72	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	7.50	SCIENTIFIC LITERATURE
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	ANTAGONIST	Ki	9.23	SCIENTIFIC LITERATURE
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	INHIBITOR	IC50	6.03	SCIENTIFIC LITERATURE
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	AGONIST	Ki	8.20	SCIENTIFIC LITERATURE
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	8.59	SCIENTIFIC LITERATURE
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	ANTAGONIST	Ki	9.77	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	6.85	SCIENTIFIC LITERATURE
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	8.42	SCIENTIFIC LITERATURE
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	9.70	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		Ki	10.05	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		Ki	8.64	CHEMBL

External reference:

ID	Source
D10309	KEGG_DRUG
4034625	VUID
N0000191737	NUI
4034625	VANDF
CHEBI:134716	CHEBI
CHEMBL2105760	ChEMBL_ID
C000591922	MESH_SUPPLEMENTAL_RECORD_UI
7672	IUPHAR_LIGAND_ID
DB09128	DRUGBANK_ID
1658314	RXNORM
234913	MMSL
31120	MMSL
d08373	MMSL
016270	NDDF
716069007	SNOMEDCT_US
781292006	SNOMEDCT_US
C3885614	UMLSCUI
9552	INN_ID
11978813	PUBCHEM_CID
2J3YBM1K8C	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Brexpiprazole	Human Prescription Drug Label	1	27241-204	TABLET	0.25 mg	ORAL	ANDA	32 sections
Brexpiprazole	Human Prescription Drug Label	1	27241-205	TABLET	0.50 mg	ORAL	ANDA	32 sections
Brexpiprazole	Human Prescription Drug Label	1	27241-206	TABLET	1 mg	ORAL	ANDA	32 sections
Brexpiprazole	Human Prescription Drug Label	1	27241-207	TABLET	2 mg	ORAL	ANDA	32 sections
Brexpiprazole	Human Prescription Drug Label	1	27241-208	TABLET	3 mg	ORAL	ANDA	32 sections
Brexpiprazole	Human Prescription Drug Label	1	27241-209	TABLET	4 mg	ORAL	ANDA	32 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-035	TABLET	0.25 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-035	TABLET	0.25 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-035	TABLET	0.25 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-036	TABLET	0.50 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-036	TABLET	0.50 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-036	TABLET	0.50 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-037	TABLET	1 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-037	TABLET	1 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-037	TABLET	1 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-038	TABLET	2 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-038	TABLET	2 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-038	TABLET	2 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-039	TABLET	3 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-039	TABLET	3 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-039	TABLET	3 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-040	TABLET	4 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-040	TABLET	4 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-040	TABLET	4 mg	ORAL	NDA	37 sections
brexpiprazole	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1649	TABLET, FILM COATED	0.25 mg	ORAL	ANDA	29 sections
brexpiprazole	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1650	TABLET, FILM COATED	0.50 mg	ORAL	ANDA	29 sections
brexpiprazole	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1651	TABLET, FILM COATED	1 mg	ORAL	ANDA	29 sections
brexpiprazole	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1652	TABLET, FILM COATED	2 mg	ORAL	ANDA	29 sections
brexpiprazole	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1653	TABLET, FILM COATED	3 mg	ORAL	ANDA	29 sections
brexpiprazole	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1654	TABLET, FILM COATED	4 mg	ORAL	ANDA	29 sections